Chromium (III) Complexes of Metformin, Dapagliflozin, Vildagliptin and Glimepiride Potentiate Antidiabetic Activity in Animal Model
Fahima Aktar, Md Zakir Sultan, Mohammad A Rashid · International Journal of Current Research and Review · 2021
Introduction: Diabetes is a chronic disease which increases morbidity, mortality along with social and economic costs.Chromium [Cr(III)] is a trace element which plays an important role in glucose and lipid metabolism i.e. in the treatment of diabetes.Objective: To synthesize some new chromium complexes with different classes of oral antidiabetic drugs and studied their antidiabetic potentials in mice.Methods: To increase the therapeutic efficacy of the drugs i.e, Metformin, Dapagliflozin, Vildagliptin and Glimepiride, Cr(III) complexes of these drugs were prepared and characterized by TLC, DSC, TGA and FTIR spectroscopy.The antidiabetic activity of the complexes was also evaluated in mice model.Results: At a dose of 150 mg/kg body weight of Cr(III)-drug complexes, the serum glucose levels reduced by 20.61% for Crmetformin( Cr-Met), 13.07% for Cr-dapagliflozin (Cr-Dapa), 7.61% for Cr-vildagliptin (Cr-Vilda) and 4.07% for Cr-glimepiride (Cr-Glim) than the corresponding parent drugs metformin, dapagliflozin, vildagliptin and glimepiride, respectively after 14 days of treatment.Conclusion: The complexes were found to be effective in lowering the serum glucose level in alloxan-induced diabetic mice.